In early 2022, the Bill and Melinda Gates Foundation (BMGF), in an effort to foster neglected disease drug discovery in countries that are most affected by these diseases, awarded a grant jointly to the University of Ghana in Accra, the Noguchi Memorial Institute for Medical Research (NMIMR, a biology research facility that is part of the University of Ghana), and the Kwame Nkrumah University of Science and Technology (KNUST) in Kumasi, to establish a collaborative drug discovery program in Ghana. The…

Lgenia’s Chief Executive Officer and Chief Scientific Officer, Dr. Philip Hipskind, recently multi-authored the paper “The Tuberculosis Drug Accelerator at year 10: what have we learned?” in the journal Nature Medicine. The Tuberculosis Drug Accelerator, an experiment designed to facilitate collaboration in tuberculosis drug discovery by breaking down barriers among competing labs and institutions, has reached a 10-year landmark. The paper reviews the consortium’s achievements, advantages, and limitations and advocates for the application of similar models to other diseases. Learn…

Indianapolis, Indiana; March 2, 2020 – LGENIA, an Indiana-based biotechnology company which has to date focused on its partnership with the TB Drug Accelerator (sponsored by the Bill and Melinda Gates Foundation) announces today that it will collaborate with the Indiana University School of Medicine to discover new medicines for Alzheimer’s disease. The IU School of Medicine was recently awarded a $36 million grant from the National Institutes of Health to create an Alzheimer’s disease drug discovery center with the…

At the spring 2018 meeting of the Bill and Melinda Gates Foundation’s TB Drug Accelerator, two new institutions were elected as full member collaborators – Harvard University and LGENIA! We now join 20 other member organizations in this important mission, and we are proud to be the first biotechnology company on their team.